Showing 2491-2500 of 4166 results for "".
- MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the ARVO 2022 Annual Meetinghttps://modernod.com/news/meiragtx-presents-clinical-data-on-botaretigene-sparoparvovec-for-the-treatment-of-x-linked-retinitis-pigmentosa-at-the-arvo-2022-annual-meeting/2480844/MeiraGTx Holdings plc announced that additional clinical data from the phase 1/2 trial of botaretigene sparoparvovec for the treatment of x-linked retinitis pigmentosa (XLRP) were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colo
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- 2020 On-Site Mobile Clinic Achieves Excellent Air Quality and Professional Standards with STERIS and Emmes Optym Certificationhttps://modernod.com/news/2020-on-site-mobile-clinic-achieves-excellent-air-quality-and-professional-standards-with-steris-and-emmes-optym-certification/2478674/On-site, a Boston-based provider of mobile vision care services, is the first mobile clinic in the industry to receive certifications from Emmes Optym and STERIS for excellent air quality, COVID-19 protocols and professional standards, according t0 a company news release. These certifications com
- Visus Therapeutics Launches and Announces Clinical Development Program for Novel Presbyopia Eye Drophttps://modernod.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/Visus Therapeutics announced its launch and clinical development program for a novel eye drop designed to restore the loss of near vision associated with presbyopia. Visus’ lead product candidate is Brimochol, a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase 3 REVERSE Clinical Trialhttps://modernod.com/news/gensight-biologics-reports-sustained-quality-of-life-improvements-at-week-72-of-phase-3-reverse-clinical-trial/2479619/GenSight Biologics reported that week 72 analyses of the data from its phase 3 REVERSE clinical trial revealed a sustained improvement in composite scores and selected sub-scores of a questionnaire used to measure patient perceptions of vision-related quality of life and ability to carry out dail
- Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of Luxturnahttps://modernod.com/news/spark-therapeutics-presents-three-post-hoc-analyses-from-phase-3-clinical-trial-of-luxturna/2479721/Spark Therapeutics announced findings from three post-hoc analyses of data from the phase 3 clinical trial of Luxturna (voretigene neparvovec-rzyl) at the American Academy of Ophthalmology annual meeting in Chicago. Luxturna is a 1-time gene therapy for the treatment of patients with vision loss
- Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-presents-dry-eye-disease-phase-2a-clinical-trial-results-at-arvo/2480191/Aldeyra Therapeutics presented the results of a randomized, double-masked, parallel-group phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a fo
- NEJM Publishes Study Demonstrating Vision Restoration with Brain-Computer Interface Retinal Implanthttps://modernod.com/news/nejm-publishes-study-demonstrating-vision-restoration-with-brain-computer-interface-retinal-implant/2484211/The New England Journal of Medicine (NEJM) published results from a clinical trial demonstrating that Science Corporation’s PRIMA brain-computer interface (BCI) retinal implant can restore functional
- Wolfe Eye Clinic Performs First Surgery in Clinical Trial Evaluating an Investigational Gene Therapy for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/wolfe-eye-clinic-performs-first-surgery-in-clinical-trial-evaluating-an-investigational-gene-therapy-for-geographic-atrophy-secondary-to-dry-amd/2478676/Wolfe Eye Clinic announced today that Jared Nielsen, MD, Retina Disease Specialist at Wolfe Eye Clinic, was recently the third surgeon in the United States and first in the Midwest to perform surgery in a clinic trial evaluating an i